Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Evoke Pharma (EVOK) Common Equity (2020 - 2025)

Historic Common Equity for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to $3.4 million.

  • Evoke Pharma's Common Equity fell 2336.15% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 2336.15%. This contributed to the annual value of $7.0 million for FY2024, which is 37284.0% up from last year.
  • According to the latest figures from Q3 2025, Evoke Pharma's Common Equity is $3.4 million, which was down 2336.15% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's Common Equity ranged from a high of $7.8 million in Q1 2021 and a low of -$2.6 million during Q4 2023
  • Its 5-year average for Common Equity is $3.7 million, with a median of $4.1 million in 2022.
  • As far as peak fluctuations go, Evoke Pharma's Common Equity surged by 169646.49% in 2021, and later tumbled by 16315.2% in 2023.
  • Over the past 5 years, Evoke Pharma's Common Equity (Quarter) stood at $3.6 million in 2021, then rose by 14.9% to $4.1 million in 2022, then plummeted by 163.15% to -$2.6 million in 2023, then soared by 372.84% to $7.0 million in 2024, then plummeted by 52.23% to $3.4 million in 2025.
  • Its last three reported values are $3.4 million in Q3 2025, $4.4 million for Q2 2025, and $5.8 million during Q1 2025.